hucMSC-sEVs-Derived 14-3-3ζ Serves as a Bridge between YAP and Autophagy in Diabetic Kidney Disease

Siqi Yin,1,2 Wanzhu Liu,1 Cheng Ji,2 Yuan Zhu,1 Yunjie Shan,2 Zixuan Zhou,2 Wenya Chen,2 Leilei Zhang,2 Zixuan Sun,2 Wenqin Zhou,1 and Hui Qian2,3

1Department of Emergency Medicine, The Affiliated People’s Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, China
2Key Laboratory of Laboratory Medicine of Jiangsu Province, Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang 212013, Jiangsu, China
3NHC Key Laboratory of Medical Embryogenesis and Developmental Molecular Biology & Shanghai Key Laboratory of Embryo and Reproduction Engineering, Shanghai 200040, China

Correspondence should be addressed to Wenqin Zhou; 553246128@qq.com and Hui Qian; lstmmmlst@163.com

Received 28 May 2022; Revised 6 August 2022; Accepted 26 August 2022; Published 22 September 2022

Academic Editor: Chaoliang Tang

Copyright © 2022 Siqi Yin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

As nanoscale membranous vesicles, human umbilical cord mesenchymal stem cell-derived small extracellular vesicles (hucMSC-sEVs) have attracted extensive attention in the field of tissue regeneration. Under the premise that the mechanisms of hucMSC-sEVs on the treatment of diabetic kidney disease (DKD) have not been revealed clearly, we constructed DKD rat model with success. After tail vein injection, hucMSC-sEVs effectively reduced blood glucose, maintained body weight and improved renal function in DKD rats. Notably, we found that hucMSC-sEVs suppressed YAP expression in renal cortical regions. Further in vitro experiments, we confirmed that the expression of YAP in the nucleus of renal podocytes was increased, and the level of autophagy was inhibited in the high-glucose environment, which could be reversed by intervention with hucMSC-sEVs. We screened out the key protein 14-3-3ζ, which could not only promote YAP cytoplasmic retention instead of entering the nucleus, but also enhance the level of autophagy in the cytoplasm. Ultimately, excessive YAP protein was removed by autophagy, a classic way of protein degradation. In conclusion, our study provides new strategies for the prevention of DKD and proposes the possibility of hucMSC-sEVs becoming a new treatment for DKD in the future.

1. Introduction

Diabetic kidney disease (DKD) is one of the most serious microvascular complications of diabetes mellitus and the leading cause of death and disability in end-stage renal disease (ESRD) patients [1, 2]. DKD is associated with increased stromal expansion, which is characterized by diffuse or nodular expansion of the mesangium and diffuse thickening of the glomerular and tubular basement membranes [3]. Podocytes, attached to the outside of the glomerular basement membrane (GBM), and their structural and functional changes are extremely important in the development and progression of DKD, which are mainly manifested in abnormal podocyte hypertrophy, disappearance, and apoptosis [4–6]. Currently, the clinical treatment strategies for DKD are blood glucose control, renin-angiotensin system inhibitors combined with multidisciplinary treatment, supplemented by reasonable and moderate regular exercise [7], etc., whereas patients have long-term dependence on drugs and are prone to side effects such as hypoglycemia, hemolytic anemia, liver, and kidney damage. Thus, it is urgent to find new strategies for the treatment of DKD.

Stem cell therapy provides an alternative strategy for modulating complex disease processes by inhibiting pathogenic mechanisms and promoting tissue regeneration [8]. It has been demonstrated that mesenchymal stem cells (MSCs) could delay the progression of DKD by inhibiting the inflammatory response and reducing kidney damage [9–11]. In addition, MSC-conditioned medium has been confirmed that it could inhibit oxidative stress and alleviate
Figure 1: Continued.
renal fibrosis caused by DKD, which revealed that MSCs could act through paracrine mechanism [12, 13]. In recent years, small extracellular vesicles (sEVs), the main paracrine components of MSCs, have set off a research boom. As important carriers of intercellular information transfer, they can selectively encapsulate proteins, nucleic acids (miRNAs, lncRNAs, and circRNAs), lipids, and are potential targets for clinical treatment [14–16]. As we previously demonstrated, the human umbilical cord mesenchymal stem cell-derived small extracellular vesicles (hucMSC-sEVs) acted a part in repairing tissue injury, such as liver failure [17], skin damage [18, 19], acute kidney injury [20, 21], and unilateral ureteral obstruction (UUO)-induced renal fibrosis [22]. However, whether and how hucMSC-sEVs protect against DKD remains unclear.

The related studies have elucidated the functions of Hippo-YAP signaling in the maintenance of glomerular development and filtration barriers, podocyte homeostasis, renal epithelial damage, and renal fibrosis in DKD [23, 24]. Yes-associated protein (YAP), a multifunctional intracellular connexin and transcriptional coactivator, is the core effector of Hippo signaling pathway, which plays a key role in signal transduction and gene transcription regulation in cells [25]. Phosphorylation of a key serine (Ser 127) of YAP in mammals confines the protein to the cytoplasm and no longer takes effect in target gene expression, which is regulated by 14-3-3ζ protein [26]. YAP has been confirmed to be closely related to renal fibrosis [22, 27], cell apoptosis [28], and epithelial-mesenchymal transition [29]. Previous study by our team has confirmed that the hucMSC-sEVs-derived 14-3-3ζ coordinated the Wnt signaling pathway by regulating YAP during skin regeneration [30]. Nevertheless, the function of YAP in DKD needs further exploration.

14-3-3 proteins include a highly conserved family of proteins that are widely present in different eukaryotic cells [31]. 14-3-3 protein has various isoforms including β, ε, η, γ, τ, σ, and ζ [32], which is widely involved in the regulation of biological processes, such as protein trafficking, signal transduction, cell cycle, apoptosis, and autophagy [33, 34]. Autophagy is a cellular self-protection that keeps cells from damage by degrading organelles and proteins [35]. In cisplatin-induced AKI models, we have demonstrated that hucMSC-sEVs-14-3-3ζ enhanced autophagy levels and reduced cell apoptosis [21, 36]. Emerging evidence suggested that dysregulated autophagy may contribute to renal glomerular and tubulointerstitial lesions in DKD [37, 38].
Blood glucose (mmol/L)  

Weight (g)  

Ser cr (𝜇mol/L)  

Kidney weight/ body weight (%)  

Time (Week)  

(a)  

(b)  

(c)  

(d)  

(e)  

Figure 2: Continued.
this reason, autophagy performs a key role in the progression of DKD. However, whether hucMSC-sEVs delivered 14-3-3ζ can induce the activation of autophagy to prevent renal injury in DKD is unclear.

This study aimed to investigate whether hucMSC-sEVs could effectively alleviate DKD and the underlying molecular mechanisms. On the one hand, our results confirmed that hucMSC-sEVs-delivered 14-3-3ζ induced phosphorylation at Ser 127 and cytoplasmic retention of YAP. On the other hand, it also has been verified that hucMSC-sEVs-14-3-3ζ could enhance autophagy in podocytes. Then it was surprisingly found that YAP, retained in the cytoplasm, was encapsulated into autophagosomes, which further promoted the degradation of YAP. Taken together, these findings underscore the importance of hucMSC-sEVs in DKD injury repair and provide a theoretical basis for the prevention and treatment of DKD.

2. Materials and Methods

2.1. Ethics. All the experimental protocols were approved by the Medical Ethics Committee and Ethics Committee for Experimental Animals of Jiangsu University (2020161).

2.2. Cell Culture. The isolation and characterization of hucMSCs is briefly introduced as follows [39]. Fresh human umbilical cord tissues were collected from the affiliated hospital of Jiangsu University and processed into 1-mm² tissue blocks within 2h. HucMSCs were cultured in minimal essential medium alpha (α-MEM) containing 10% fetal bovine serum (FBS, Gibco) at 37°C with 5% CO₂. We subsequently expanded a large number of hucMSCs and collected the supernatant of the 3rd to 5th generation. Rat podocytes were purchased from American Type Culture Collection (ATCC) and maintained in low-glucose DMEM with 10% fetal bovine serum at 37°C with 5% CO₂.

2.3. hucMSC-sEVs Purification and Characterization. HucMSC-sEVs were isolated and purified by differential ultracentrifugation [40]. The final content was resuspended in PBS and subsequently passed through a 0.22-μm filter to remove bacteria. The hucMSC-sEVs were stored at -80°C for long-term use. The protein contents of the purified hucMSC-sEVs were detected by bicinchoninic acid (BCA) protein assay kit (Vazyme). The morphologies of hucMSC-sEVs were observed by TEM (FEI Tecnai 12, Philips). The sizes and concentrations of hucMSC-sEVs were detected by NTA (NanoSight, Amesbury). The expression of hucMSC-sEVs surface markers, including CD9, CD81, and TSG101, and the lack of Calnexin and Albumin expression were determined by western blot.

2.4. Diabetic Kidney Disease Rat Model. Aged 8 weeks male Sprague-Dawley (S-D) rats, weight within 200-250 g, were purchased from Charles River (Beijing, China). The rats were fed with a regular diet at an ambient temperature of 22-25°C for 5 days and then fed with 45% high fat diet (HFD) for 4 weeks. After being fasted for 12 h with free access to water, HFD fed rats were treated with STZ (35 mg/kg in 0.1 M citrate buffered saline, pH = 4.5) via tail vein injection [41]. Random fasting blood glucose (≥16.7 mmol/L) was measured to evaluate whether the rat models were successful. Eight weeks later, hucMSC-sEVs (10 mg/kg) were injected into DKD rats through tail vein intravenously. Normal rats were fed with normal diet as control. All rat models were harvested 24 weeks after STZ injection, and the kidney tissues were sacrificed for follow-up experiments.

2.5. hucMSC-sEVs Labeling and Internalization. According to the manufacturer’s protocol, hucMSC-sEVs were labeled with fluorochrome Dil (Red, Thermo Fisher). Then hucMSC-sEVs in PBS were mixed with Dil in the dark at 37°C for 30 min. The labeled sEVs were washed with PBS and filtered through a 100-kDa-molecular-weight cut-off ultrafiltration membrane (Millipore) at 1000 g for 30 min to remove the unbound dye. PBS was used as a negative control. Podocytes (1 × 10⁴ per well) were seeded in 6-well plates and incubated with Dil-labeled hucMSC-sEVs at 37°C for 12 h. The cells were washed with PBS and fixed in 4% paraformaldehyde. Nucleus were counterstained with Hoechst 33342 (Sigma). A confocal microscope was used...
Figure 3: Continued.
Figure 3: Continued.
to acquire sequentially fluorescent images (Thermo Fisher Scientific).

2.6. Cytoplasm and Nuclear Fractionation. Cytoplasm and nuclear fractionation was performed according to the manufacturer’s instructions (Vazyme). Cells were suspended in isolation buffer A mixed with protease inhibitors and rotated at 4°C for 1 min. After 12,000 g centrifugation at 4°C for 5 min, supernatant was collected containing the cytoplasm fraction. The remaining cell debris were then suspended in isolation buffer B mixed with protease inhibitors and rotated at 4°C for 1 min and repeated three times every 10 min. Cytoplasm and nuclear fractionation were detected by western blot.

2.7. Knockdown of 14-3-3ζ in hucMSCs. To target 14-3-3ζ genes silence, a lentiviral expression vector containing the 14-3-3ζ shRNA sequence (Sigma) was designed and Lenti-GFP-shRNA as negative control vector. The Lenti-14-3-3ζ shRNA vectors were generated by ligating the vector Tet-pLKO-puro with 14-3-3ζ shRNA oligonucleotides (FUBio). To obtain sequences information of 14-3-3ζ shRNA oligonucleotides, please browse Table S1 in the Supplementary Material. HucMSCs were transduced with the prepared lentivirus (Lenti-14-3-3ζ shRNA or Lenti-GFP shRNA) at the suitable dosage and selected with 1 μg/mL of puromycin (Invitrogen) for 15 days. The efficiency of 14-3-3ζ knockdown was evaluated by western blot.

2.8. Western Blot. Total proteins from kidney tissues and cells were extracted in radioimmunoprecipitation assay (RIPA) buffer. Equal protein amounts of tissue or cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) at 12% or 15% and transferred to polyvinylidene fluoride (PVDF) membranes superior. After being blocked with 5% skim milk for 1 h, the...
Figure 4: Continued.
membranes were incubated with primary antibodies and horseradish peroxidase (HRP)-conjugated secondary antibodies and then detected by using an enhanced chemiluminescent (ECL) substrate detection system. Primary antibodies were incubated overnight at 4°C. The HRP-conjugated goat antirabbit and goat antimouse secondary antibodies (CWBIO) were incubated 90 min at RT. For more antibodies information, all primary antibodies involved in this study are summarized in Table S2 in the Supplementary Material.

2.9. Cell Transfection and Structured Illumination Microscopy Assay. Podocytes were seeded at 6-well plates and cultured for 24 h and then transfected mRFP-GFP-LC3 adenovirus according to the manufacturer’s protocol (Han Heng Biology). After treatment, the cells were washed with PBS and fixed with 4% paraformaldehyde. Finally, the cells were then stained with Hoechst33342 for nuclear staining. The images were acquired with a structured illumination microscopy (Nikon, SIM). The yellow puncta were autophagosomes, and the red puncta were autolysosomes.

2.10. Immunoprecipitation (IP). The cell pellet was collected in Co-IP buffer (Pierce™), and then the supernatant was subjected to IP using the indicated primary antibodies at 4°C overnight. The lysate was centrifuged and incubated with 30 μL protein A/G gel at 4°C for 4 h. The collected protein complexes were washed 4 times with Co-IP buffer and analyzed by western blot. Catalogue number is listed in Supplementary Table S3.

2.11. Immunofluorescence and Immunohistochemistry Analysis. Podocytes were fixed in 4% paraformaldehyde for 60 min, then treated with 0.1% Triton membrane breaker for 20 min. The kidney tissue slices were deparaffinized. The primary antibodies were incubated at 4°C overnight. After washing with PBS, cells were incubated with goat anti-Mouse IgG, Alexa Fluor 488 (Invitrogen) or goat anti-rabbit IgG, Alexa Fluor 555 (Invitrogen) at RT for 2 h. Nucleus were stained with Hoechst33342. Images were captured with a fluorescent microscope (Nikon) or a structured illumination microscope (Nikon, SIM). The slides were visualized with a confocal microscope (DeltaVision Elite, GE).

2.12. QRT-PCR. Total RNA from podocytes was extracted with TRIzol reagent. cDNA was reversed according to the SuperScript™ II RT kit manufacturer’s instructions (Vazyme). The qRT-PCR was used to detect the expression levels of the target genes. β-Actin was used as the endogenous control. The specific primers were produced by Sangon Biotech, and their products are shown in Supplementary Table S4.

Figure 4: YAP was held in the cytoplasm by hucMSC-sEVs-derived 14-3-3ζ. (a) The lentiviral expression vectors containing the 14-3-3ζ shRNA sequence was designed and Lenti-GFP-shRNA as negative control vector. The lentiviral transfection efficiency was observed by fluorescence microscopy under different MOI values (bar = 1000 μm). (b) Western blot experiments verified the knockdown efficiency of 14-3-3ζ. (c) The hucMSC-sEVs were labeled with fluorescent dye Dil and incubated with podocytes for 24 h. The podocytes were observed by confocal microscope to observe the endocytosis of sEVs (bar = 25 μm). (d) Co-IP confirmed the binding of 14-3-3ζ to YAP phosphorylated at serine 127. (e) Nuclear-cytoplasmic separation assays were validated by western blot to measure cytoplasmic, nuclear, and total (p-)YAP levels (n = 3). (f) Statistical analysis of protein expression. (g) Cellular immunofluorescence was used to observe the apoptosis of podocytes (bar = 25 μm). (n = 3; * p < 0.05, ** p < 0.01, and *** p < 0.001).
Figure 5: Continued.
Relative protein expression/\(\beta\)-actin

|      | ULK1 | Beclin | LC3B-II | YAP |
|------|------|--------|---------|-----|
| 5.5 mM |      |        |         |     |
| 30 mM  |      |        |         |     |
| shGFP-sEVs |      |        |         |     |
| sh14-3-3-\(\zeta\)-sEVs |      |        |         |     |
| hucMSC-sEVs |      |        |         |     |

(d)

(d)

(e)

(e)

% Apoptotic cell

| 5.5 mM | 30 mM | shGFP-sEVs | sh14-3-3-\(\zeta\)-sEVs | hucMSC-sEVs |
|--------|-------|------------|-------------------------|------------|
| 3.78%  | 1.90% | 4.87%      | 7.00%                   | 3.04%      |
| 1.90%  | 7.00% | 1.79%      | 1.90%                   | 4.87%      |
| 3.04%  | 1.79% | 7.00%      | 1.90%                   | 4.87%      |
| 4.87%  | 1.90% | 7.00%      | 1.90%                   | 4.87%      |
| 7.00%  | 1.90% | 4.87%      | 1.90%                   | 4.87%      |

(f)

Figure 5: Continued.
2.13. Statistical Analysis. All data are expressed as mean ± standard deviation (SD) by using Prism software (GraphPad, San Diego). The statistically significant differences between different groups were assessed using one-way analysis of variance (ANOVA) followed by Turkey’s posttest. p values were adjusted for multiple comparisons when appropriate. p < 0.05 was considered statistically significant.

3. Results

3.1. The Characteristics of hucMSCs and hucMSC-sEVs. Human umbilical cord tissues were purified and isolated as previously described. After 2 weeks, the hucMSCs were closely arranged around the umbilical cord tissue, which looked like long spindle-shaped and fish-like growth (Figures 1(a) and 1(b)). After cultured in osteogenic and adipogenic medium, Oil-Red-O staining revealed numerous lipid droplets in the hucMSC cytoplasm, and the cells became alkaline phosphatase positive (Figures 1(c) and 1(d)). These results showed that hucMSCs could be differentiated into both adipocytes and osteoblasts. Flow cytometry analysis demonstrated that hucMSCs highly express typical MSC surface markers, including CD29, CD166, and CD44, with the low expression of CD45, HLA-DR, and CD14.
Oxidative Medicine and Cellular Longevity

3.2. High-Expressed YAP Was Attenuated by hucMSC-sEVs in High-Glucose Environment. After establishing a 24-week DKD rat model successfully, we injected hucMSC-sEVs at a dose of 10 mg/kg through the tail vein to observe the repair effect. Compared with normal and DKD groups, the intervention of hucMSC-sEVs effectively improved the symptoms of the DKD rats, which has reflected in a certain degree of hypoglycemic effect, maintaining a better body weight and reducing the levels of creatinine and urea nitrogen (Figure 2(a)). By means of hematoxylin-eosin staining (H-E staining) and YAP immunohistochemistry on renal tissue sections, pathological damage such as glomerular basement membrane thickening and renal tubular dilatation in DKD rats could be observed. The expression of YAP increased at the same time. hucMSC-sEVs inhibited the expression of YAP and alleviated renal tissue damage (Figure 2(b)). In vitro, first we stimulated podocytes with different gradients of glucose and found that 30 mM was the optimal concentration for high-glucose treatment (Supplementary Figure S1A-D). Immunofluorescence results of podocytes showed increased expression and entry of YAP into the nucleus, accompanied by decreased expression of the podocyte function-specific marker NPHS2, which were corrected after the intervention of hucMSC-sEVs (Figure 2(d)). Furthermore, treatment of podocytes in a high-glucose environment with insulin did not attenuate YAP expression nor inhibit YAP entry into the nucleus significantly, whereas hucMSC-sEVs did (Figure S1E-H). It was also confirmed from the mRNA level that YAP and its related transcription factors were highly expressed in high-glucose-induced podocytes and hucMSC-sEVs could effectively attenuate their expression (Figure 2(c)). It was more intuitively observed by immunofluorescence that hucMSC-sEVs could effectively reduce the expression of YAP in the glomerular region of DKD rats, that is, hucMSC-sEVs could alleviate podocyte dysfunction caused by DKD. In addition, immunohistochemical staining showed that the number of cells positive for the podocyte nuclear marker WT1 was significantly decreased in the DKD group, while the number of podocytes increased after the hucMSC-sEVs intervention, which alleviated the podocyte loss that occurred during the DKD period (Figures 2(e) and 2(f)).

3.3. hucMSC-sEVs Reversed High Glucose-Induced Low-Level Autophagy in Podocytes. Flow cytometry analysis showed that under continuous high-glucose stimulation, the level of autophagy-related proteins (LC3B, p62, and Beclin) in podocytes were inhibited, which could be alleviated by hucMSC-sEVs (Figures 3(a) and 3(b)). After that, double-labeled LC3 (mRFP-GFP-LC3) lentivirus was transfected into podocytes for 48 h, and then high glucose and high glucose with hucMSC-sEVs were given. Subsequently, the intervention of chloroquine, an autophagy inhibitor, was used to further explore the changes in autophagy levels under different processing conditions. In the transfected podocytes, both the chloroquine group and the high-glucose treatment group appeared stronger GFP signal compared with the normal group, whereas the intervention of hucMSC-sEVs could effectively weaken the intensity of GFP signal (Figure 3(c)). The results of flow cytometry analysis showed that hucMSC-sEVs could mitigate the cell apoptosis of high glucose and/or chloroquine on podocytes (Figures 3(d) and 3(e)). The changes of autophagy-related proteins and proliferation-apoptosis-related proteins in podocytes were consistent with the above phenomenon (Figures 3(f) and 3(g)). Podocyte autophagosomes and autophagolysosomes were observed by transmission electron microscopy, and it was found that hucMSC-sEVs could promote the occurrence of autophagy (Figures 3(h) and 3(i)).

3.4. YAP Was Held in the Cytoplasm by hucMSC-sEVs-Derived 14-3-3ζ. We screened the highly expressed 14-3-3ζ protein by LC-MS/MS analysis of hucMSC-sEVs. In order to verify the role of 14-3-3ζ, we constructed a 14-3-3ζ lentivirus stable transfection system for hucMSC cells (Figure 4(a)), and the knockdown efficiency was verified by protein surface labeling (Figure 4(b)). hucMSC-sEVs were labeled with Dil and uptake by podocytes (Figure 4(c)). Co-IP experiments confirmed that compared with the GFP control group, the expression of phosphorylated YAP at serine 127 in podocytes was reduced after the intervention of knockdown 14-3-3ζ-sEVs (Figure 4(d)). Further separation of nucleoplasmic proteins in podocytes verified that the nuclear translocation of YAP increased in a high-glucose environment. hucMSC-sEVs effectively inhibited YAP from entering the nucleus and blocking in the cytoplasm, which worked by 14-3-3ζ (Figures 4(e) and 4(f)). The apoptosis level of podocytes was clearly visualized by the fluorescence intensity and localization of Caspase3. The results confirmed that knockdown of 14-3-3ζ in hucMSC-sEVs could decrease the podocytes apoptosis to a certain extent (Figure 4(g)).

3.5. hucMSC-sEVs-14-3-3ζ Enhanced Autophagy to Engulf YAP. After verifying the critical role of hucMSC-sEVs-14-3-3ζ on YAP, we still investigated the regulatory mechanism of 14-3-3ζ on autophagy. The structured illumination microscopy (SIM) was applied to observe the production of autophagosomes. The yellow puncta represented autophagosomes, and the red puncta were autolysosomes. The expression and the puncta of autophagosomes were decreased in the sh14-3-3ζ-sEVs group compared with the shGFP-sEVs group and the hucMSC-sEVs group (Figures 5(a) and 5(b)). Western blot results further confirmed that knockdown of 14-3-3ζ significantly suppressed the expression of autophagy-related proteins (Figures 5(c)
and 5(d)). The number of apoptotic cells had significantly increased in sh14-3-3ζ-sEVs group compared with the control group, whereas pretreatment with hucMSC-sEVs resulted in fewer apoptotic cells (Figures 5(e) and 5(f)). Moreover, we unexpectedly found that the expression of YAP did not decline after the intervention of the autophagy inhibitor chloroquine (Figure 3(f)). Consequently, YAP was confirmed to colocalize with perinuclear LC3B in podocytes after chloroquine pretreatment (Figure 5(g)). It has been confirmed that YAP was enclosed in autophagosomes.

4. Discussion

Diabetic kidney disease (DKD) has become the leading cause of chronic kidney disease, placing a huge burden on the economy and society. The onset of DKD is insidious in the early stage, and the patients only pay attention to it when the symptoms of polydipsia and polyuria occur, so that it develops to advanced renal failure and even uremia. Due to the complex pathogenesis of DKD and the lack of specific and effective intervention targets, there is currently no breakthrough in treatment [42]. As far as the current clinical treatment of DKD is concerned, it is limited to only renin-angiotensin system inhibitors combined with multidisciplinary therapy [43]. Despite the addition of new clinical trials with renal outcomes as the primary endpoint, the progression of DKD has not been fully controlled. Therefore, it is urgent to find new treatment methods for DKD.

In the twenty-first century, stem cell therapy has opened the door to the medical field. Stem cells can be used as ideal “seed” cells for the repair of tissue and organ damage caused by pathological changes due to their high-efficiency proliferation, multidirectional differentiation potential, immune regulation, and self-replication [44]. Umbilical cord, adipose, and bone marrow-derived MSCs have been proved to have effects of inhibiting inflammation and antifibrosis and inhibiting apoptosis in DKD [45–49]. In addition, the paracrine approach of MSCs is considered to be more superior efficacy, among which are especially small extracellular vesicles (sEVs) [50]. sEVs, which encapsulate therapeutic proteins or RNA molecules, are not only promising biomarkers but also potential targets and tools for the treatment of DKD [51]. In this study, we successfully constructed high-glucose models both in vivo and in vitro, confirming that hucMSC-sEVs could effectively lower blood glucose level and reduce renal damage. This provides new ideas for the development of DKD treatment regimens.

YAP, a transcriptional regulator, has become the focus of great interest because of its remarkable biological properties in tissue organ development and tissue homeostasis. YAP activity is critical for cell proliferation throughout organ growth, tissue renewal, and regeneration [52, 53]. Previously, we confirmed that YAP is a key molecule in the treatment of renal fibrosis and the highly expressed YAP could be degraded by the CK1δ/β-TRCP ubiquitin system carried by hucMSC-sEVs in the UUO model [22]. In the DKD model of this study, we found that YAP was highly expressed in a high-glucose environment, accompanied by renal impairment and massive cell apoptosis both in vivo and in vitro. Afterwards, the key protein molecule, 14-3-3ζ, that played a vital role in hucMSC-sEVs were screened by LC-MS/MS technology. Via knocking down the 14-3-3ζ protein, the ability of hucMSC-sEVs to weaken YAP was reduced. Meanwhile, the apoptosis of podocytes was promoted at the same time. These evidences directly illustrate the importance of 14-3-3ζ.

The 14-3-3 protein family is widely distributed in eukaryotes and participates in a variety of signal transduction pathways and important cell life activities, such as cell growth and development, gene transcription, and cell apoptosis [54, 55]. According to studies, the 14-3-3 protein regulates the process of autophagy and the formation of autophagosomes by binding to autophagy-related proteins such as Beclin and hVPS34 [56]. Autophagy is a cellular process that determines cell fate and is tightly regulated by different signaling pathways, some of which, such as MAPK, PI3K, and mTOR, are tightly regulated by the 14-3-3 protein [57]. Our previous related studies confirmed that 14-3-3ζ derived from hucMSC-sEVs could increase the level of autophagy and repair skin and acute kidney injury [19, 21]. However, in this study, we further confirmed that hucMSC-sEVs-derived 14-3-3ζ could increase the level of autophagy in podocytes and promote the formation of autophagosomes in DKD. Knockdown of 14-3-3ζ could attenuate the level of autophagy in podocytes, thus confirming the important role of 14-3-3ζ protein.

Autophagy is a highly conserved degradation system in which cellular contents such as proteins, organelles, and lipids are degraded in a lysosome-dependent manner. This may be related to the way in which p62-mediated ubiquitination-modified target proteins bind to autophagy receptors [58]. Lee et al. demonstrated that excess YAP is degraded by autophagy through the p62/Sqstm1-Neu2 axis in HCC [59]. Additional studies have shown that enhanced autophagic activity in Alzheimer’s disease promotes β-amyloid clearance in vitro and in vivo [60]. Here, we explored the “link” role of 14-3-3ζ protein in DKD. On the one hand, we first proved that the secretion of 14-3-3ζ protein from hucMSC-sEVs inhibited the entry of YAP into the nucleus and promoted its retention in the cytoplasm. On the other hand, we confirmed that 14-3-3ζ enhanced the level of autophagy in podocytes. In order to explore whether the highly expressed autophagy could remove excess YAP from the cytoplasm, the autophagy inhibitor chloroquine was used to block the formation of autophagic flux. It was found that chloroquine did not attenuate the expression of YAP, that is to say, the decrease of YAP was caused by the enhancement of autophagy. And after treated with chloroquine, YAP colocalized with perinuclear LC3B, which indicated that YAP was enclosed in autophagosomes.

In conclusion, we demonstrate that YAP exacerbates renal damage and podocyte apoptosis in DKD. hucMSC-sEVs degraded cytoplasmic retained YAP in the way of increasing the level of autophagy by delivering 14-3-3ζ. This article demonstrated the potential of hucMSC-sEVs as nanoscale biomaterials for the treatment of DKD in the future (Figure 6).
5. Conclusion

Taken together, we demonstrated that the application of hucMSC-sEVs could reduce the apoptosis of renal podocytes induced by high glucose, inhibit the high expression of YAP, promote the activation of autophagy, and exert a cytoprotective effect. These results indicated that hucMSC-sEVs could inhibit YAP from entering the nucleus and linger in the cytoplasm by transporting 14-3-3ζ protein, which was eventually devoured and cleared by autophagy. Consequently, hucMSC-sEVs can be used as a new therapeutic tool for the prevention and treatment of DKD.

Data Availability

The datasets of the current study are available from the corresponding author upon reasonable request.

Additional Points

Highlights. (i) YAP protein was highly expressed in DKD both in vitro and in vivo, which was suppressed by hucMSC-sEVs. (ii) hucMSC-sEVs carried the internal 14-3-3ζ protein to promote YAP retention in the cytoplasm. (iii) hucMSC-sEVs-14-3-3ζ promoted a surge in the level of autophagy in podocytes. (iv) YAP, retained in the cytoplasm, was phagocytosed into autophagosomes.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Siqi Yin and Wanzhu Liu contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81871496 and 82172102), the Advanced Science and Technology Foundation of the Jiangsu Province (BE2021689), the Guided Science and Technology Foundation of Zhenjiang (FZ2021060), the Research and Innovation Program for Graduate Students in Jiangsu Province (KYCX20_3090), and the Zhenjiang Key Laboratory of High Technology Research on Exosomes Foundation and Transformation Application (SS2018003), and the project was funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (Phase III).

Supplementary Materials

Supplementary 1. Supplementary Figure 1 (Figure S1): merely lowering blood sugar did not prevent YAP overexpression in DKD.

Supplementary 2. Supplementary Table 1 (Table S1): the sequences of shRNA oligonucleotides. Knockdown 14-3-3ζ shRNA oligonucleotides, both forward and reverse, are displayed in Table S1.

Supplementary 3. Supplementary Table 2 (Table S2): the detailed information about antibodies in this study. The names, detection, manufacturers, and catalogue numbers of antibodies involved in this study are generalized in Table S2.

Supplementary 4. Supplementary Table 3 (Table S3): the names, manufacturers, and catalogue numbers of the kits used in this article are listed in Table S3.

Supplementary 5. Supplementary Table 4 (Table S4): the gene names, protein names, forward, and reverse sequences of qRT-PCR primers (5′-3′).

References

[1] J. Lin, A. Cheng, K. Cheng et al., “New insights into the mechanisms of pyroptosis and implications for diabetic kidney disease,” International Journal of Molecular Sciences, vol. 21, no. 19, p. 7057, 2020.
[2] B.-C. Liu, H.-Y. Lan, and L.-L. Lv, Renal Fibrosis: Mechanisms and Therapies, Springer Singapore, 2019.
[3] M. Akhtar, N. M. Taha, A. Nauman, I. B. Mujeeb, and A. D. M. H. al-Nabet, “Diabetic kidney disease: past and present,” Advances in Anatomic Pathology, vol. 27, no. 2, pp. 87–97, 2020.
[4] C. C. Lu, G. H. Wang, J. Lu et al., “Role of podocyte injury in glomerulosclerosis,” Advances in Experimental Medicine and Biology, vol. 1165, pp. 195–232, 2019.
[5] H. Dai, Q. Liu, and B. Liu, “Research progress on mechanism of podocyte depletion in diabetic nephropathy,” Journal Diabetes Research, vol. 2017, article 2615286, 10 pages, 2017.
[6] A. Tagawa, M. Yasuda, S. Kume et al., “Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy,” Diabetes, vol. 65, no. 3, pp. 755–767, 2016.
[7] T. Yamazaki, I. Mimura, T. Tanaka, and M. Nangaku, “Treatment of diabetic kidney disease: current and future,” Diabetes and Metabolism Journal, vol. 45, no. 1, pp. 11–26, 2021.
[8] T. P. Griffin, W. P. Martin, N. Islam, T. O’Brien, and M. D. Griffin, “The promise of mesenchymal stem cell therapy for diabetic kidney disease,” Current Diabetes Reports, vol. 16, no. 5, p. 42, 2016.
[9] Y. Li, J. Liu, G. Liao et al., “Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment,” International Journal of Molecular Medicine, vol. 41, no. 5, pp. 2629–2639, 2018.
[10] L. Chen, E. Xiang, C. Li et al., “Umbilical cord-derived mesenchymal stem cells ameliorate nephrocyte injury and proteinuria in a diabetic nephropathy rat model,” Journal Diabetes Research, vol. 2020, article 8035853, 9 pages, 2020.
[11] Y. Wang, S. K. Shan, B. Guo et al., “The multi-therapeutic role of MSCs in diabetic nephropathy,” Frontiers in Endocrinology, vol. 12, p. 8035853, 2021.
[12] H. Li, P. Rong, X. Ma et al., “Mouse umbilical cord mesenchymal stem cell paracrine alleviates renal fibrosis in diabetic nephropathy by reducing myofibroblast transdifferentiation and cell proliferation and upregulating MMPs in mesangial cells,” Journal Diabetes Research, vol. 2020, article 3847171, 14 pages, 2020.
[13] S. Lv, J. Cheng, A. Sun et al., “Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting oxidative stress,” Oxidative Medicine and Cellular Longevity, vol. 2020, article 8035853, 9 pages, 2020.
stress,” *Diabetes Research and Clinical Practice*, vol. 104, no. 1, pp. 143–154, 2014.

[14] X. Zhang, X. Yuan, H. Shi, L. Wu, H. Qian, and W. Xu, "Exosomes in cancer: small particle, big player," *Journal of Hematology & Oncology*, vol. 8, no. 1, p. 83, 2015.

[15] C. He, S. Zheng, Y. Luo, and B. Wang, "Exosome theranostics: biology and translational medicine," *Theranostics*, vol. 8, no. 1, pp. 237–255, 2018.

[16] Y. Shi, H. Shi, A. Nomi, Z. Lei-lei, B. Zhang, and H. Qian, "Mesenchymal stem cell-derived extracellular vesicles: a new impetus of promoting angiogenesis in tissue regeneration," *Cytotherapy*, vol. 21, no. 5, pp. 497–508, 2019.

[17] Y. Yan, W. Jiang, Y. Tan et al., "HucMSC exosome-derived GPX1 is required for the recovery of hepatic oxidant injury," *Molecular Therapy*, vol. 25, no. 2, pp. 465–479, 2017.

[18] B. Zhang, M. Wang, A. Gong et al., "HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing," *Stem Cells*, vol. 33, no. 7, pp. 2158–2168, 2015.

[19] P. Wu, B. Zhang, X. Han et al., "HucMSC exosome-delivered 14-3-3ζ alleviates ultraviolet radiation-induced photodamage via SIRT1 pathway modulation," *Aging*, vol. 13, no. 8, pp. 11542–11563, 2021.

[20] R. Zhang, Y. Zhu, Y. Li et al., "Human umbilical cord mesenchymal stem cell exosomes alleviate sepsis-associated acute kidney injury via regulating microRNA-146b expression," *Biotechnology Letters*, vol. 42, no. 4, pp. 669–679, 2020.

[21] H. Jia, W. Liu, B. Zhang et al., "HucMSC exosomes-delivered 14-3-3ζ enhanced autophagy via modulation of ATG16L in preventing cisplatin-induced acute kidney injury," *American Journal of Translational Research*, vol. 10, no. 1, pp. 101–113, 2018.

[22] C. Ji, J. Zhang, Y. Zhu et al., "Exosomes derived from hucMSC attenuate renal fibrosis through CK16β/TRCP-mediated YAP degradation," *Cell Death & Disease*, vol. 11, no. 5, p. 327, 2020.

[23] J. S. Wong, K. Meliambro, J. Ray, and K. N. Campbell, "Hippo signaling in the kidney: the good and the bad," *American Journal of Physiology: Renal Physiology*, vol. 311, no. 2, pp. F241–F248, 2016.

[24] J. Chen, X. Wang, Q. He et al., "YAP activation in renal proximal tubule cells drives diabetic renal interstitial fibrogenesis," *Diabetes*, vol. 69, no. 11, pp. 2446–2457, 2020.

[25] Y. Deng, J. Lu, W. Li et al., "Reciprocal inhibition of YAP/TAZ and NF-κB regulates osteoarthritic cartilage degradation," *Nature Communications*, vol. 9, no. 1, p. 4564, 2018.

[26] B. Zhao, K. Tumaneng, and K. L. Guan, "The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal," *Nature Cell Biology*, vol. 13, no. 8, pp. 877–883, 2011.

[27] S. G. Szeto, M. Narimatsu, M. Lu et al., "YAP/TAZ are mechanoregulators of TGF-β-Smad signaling and renal Fibrogenesis," *Journal of the American Society of Nephrology*, vol. 27, no. 10, pp. 3117–3128, 2016.

[28] Q. Zhuang, F. Li, J. Liu et al., "Nuclear exclusion of YAP exacerbates podocyte apoptosis and disease progression in Adriamycin-induced focal segmental glomerulosclerosis," *Laboratory Investigation*, vol. 101, no. 2, pp. 258–270, 2021.

[29] Y. Li, Q. Hu, C. Li et al., "PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease," *The Journal of Clinical Investigation*, vol. 129, no. 3, pp. 1129–1151, 2019.

[30] B. Zhang, Y. Shi, A. Gong et al., "HucMSC exosome-delivered 14-3-3ζ orchestrates self-control of the Wnt response via modulation of YAP during cutaneous regeneration," *Stem Cells*, vol. 34, no. 10, pp. 2485–2500, 2016.

[31] H. Fu, R. R. Subramanian, and S. C. Masters, "14-3-3 proteins: structure, function, and regulation," *Annual Review of Pharmacology and Toxicology*, vol. 40, no. 1, pp. 617–647, 2000.

[32] Y. Aghazadeh and V. Papadopoulos, "The role of the 14-3-3 protein family in health, disease, and drug development," *Drug Discovery Today*, vol. 21, no. 2, pp. 278–287, 2016.

[33] T. Obsil and V. Obsilova, "Structural basis of 14-3-3 protein functions," *Seminars in Cell & Developmental Biology*, vol. 22, no. 7, pp. 663–672, 2011.

[34] H. Jia, Z. Liang, X. Zhang, J. Wang, W. Xu, and H. Qian, "14-3-3 proteins: an important regulator of autophagy in diseases," *American Journal of Translational Research*, vol. 9, no. 11, pp. 4738–4746, 2017.

[35] L. Yu, Y. Chen, and S. A. Tooze, "Autophagy pathway: cellular and molecular mechanisms," *Autophagy*, vol. 14, no. 2, pp. 207–215, 2018.

[36] J. Wang, H. Jia, B. Zhang et al., "HucMSC exosome-transported 14-3-3ζ prevents the injury of cisplatin to HK-2 cells by inducing autophagy in vitro," *Cytotherapy*, vol. 20, no. 1, pp. 29–44, 2018.

[37] D. Yang, M. J. Livingston, Z. Liu et al., "Autophagy in diabetic kidney disease: regulation, pathological role and therapeutic potential," *Cellular and Molecular Life Sciences*, vol. 75, no. 4, pp. 669–688, 2018.

[38] M. Yasuda-Yamahara, S. Kume, A. Tagawa, H. Maegawa, and T. Uzu, "Emerging role of podocyte autophagy in the progression of diabetic nephropathy," *Autophagy*, vol. 11, no. 12, pp. 2385–2386, 2015.

[39] C. Qiao, W. Xu, W. Zhu et al., "Human mesenchymal stem cells isolated from the umbilical cord," *Cell Biology International*, vol. 32, no. 1, pp. 8–15, 2008.

[40] W. Zhu, L. Huang, Y. Li et al., "Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo," *Cancer Letters*, vol. 315, no. 1, pp. 28–37, 2012.

[41] M. J. Reed, K. Meszaros, L. J. Entes et al., "A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat," *Metabolism*, vol. 49, no. 11, pp. 1390–1394, 2000.

[42] D. W. Liu, Z. Y. Li, and Z. S. Liu, "Treatment of diabetic kidney disease: research development, current hotspots and future directions," *Zhonghua Yi Xue Za Zhi*, vol. 101, no. 10, pp. 683–686, 2021.

[43] M. Sugahara, W. L. W. Pak, T. Tanaka, S. C. W. Tang, and M. Nangaku, "Update on diagnosis, pathophysiology, and management of diabetic kidney disease," *Nephrology (Carlton)*, vol. 26, no. 6, pp. 491–500, 2021.

[44] T. K. Giri, A. Alexander, M. Agrawal, S. Saraf, S. Saraf, and Ajazuddin, "Current status of stem cell therapies in tissue repair and regeneration," *Current Stem Cell Research & Therapy*, vol. 14, no. 2, pp. 117–126, 2019.

[45] E. Xiang, B. Han, Q. Zhang et al., "Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis," *Stem Cell Research & Therapy*, vol. 11, no. 1, pp. 336, 2020.

[46] S. Takemura, T. Shimizu, M. Oka, S. Sekiya, and T. Babazono, "Transplantation of adipose-derived mesenchymal stem cell sheets directly into the kidney suppresses the progression of..."
renal injury in a diabetic nephropathy rat model," Journal of Diabetes Investigation, vol. 11, no. 3, pp. 545–553, 2020.

[47] L. Lin, H. Lin, D. Wang, Z. Bao, H. Cai, and X. Zhang, “Bone marrow mesenchymal stem cells ameliorated kidney fibrosis by attenuating TLR4/NF-κB in diabetic rats,” Life Sciences, vol. 262, p. 118385, 2020.

[48] L. J. Hickson, A. Eirin, S. M. Conley et al., “Diabetic kidney disease alters the transcriptome and function of human adipose-derived mesenchymal stromal cells but maintains immunomodulatory and paracrine activities important for renal repair,” Diabetologia, vol. 70, no. 7, pp. 1561–1574, 2021.

[49] J. S. Li and B. Li, “Renal injury repair: how about the role of stem cells,” Advances in Experimental Medicine and Biology, vol. 1165, pp. 661–670, 2019.

[50] A. Chen, H. Wang, Y. Su et al., “Exosomes: biomarkers and therapeutic targets of diabetic vascular complications,” Frontiers in Endocrinology, vol. 12, p. 720466, 2021.

[51] L. L. Lv, “Role of extracellular vesicles in renal inflammation and fibrosis,” Advances in Experimental Medicine and Biology, vol. 1165, pp. 455–466, 2019.

[52] S. Piccolo, S. Dupont, and M. Cordenonsi, “The biology of YAP/TAZ: hippo signaling and beyond,” Physiological Reviews, vol. 94, no. 4, pp. 1287–1312, 2014.

[53] C. Xie, X. Shen, X. Xu et al., “Astrocytic YAP promotes the formation of glia scars and neural regeneration after spinal cord injury,” The Journal of Neuroscience, vol. 40, no. 13, pp. 2644–2662, 2020.

[54] A. Aitken, “14-3-3 proteins: a historic overview,” Seminars in Cancer Biology, vol. 16, no. 3, pp. 162–172, 2006.

[55] J. Zhao, C. L. Meyerkord, Y. Du, F. R. Khuri, and H. Fu, “14-3-3 proteins as potential therapeutic targets,” Seminars in Cell & Developmental Biology, vol. 22, no. 7, pp. 705–712, 2011.

[56] M. Pozuelo-Rubio, “Regulation of autophagic activity by 14-3-3ζ proteins associated with class III phosphatidylinositol-3-kinase,” Cell Death & Differentiation, vol. 18, no. 3, pp. 479–492, 2011.

[57] M. Pozuelo-Rubio, “14-3-3 proteins are regulators of autophagy,” Cell, vol. 1, no. 4, pp. 754–773, 2012.

[58] S. Pankiv, T. H. Clausen, T. Lamark et al., “p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy,” The Journal of Biological Chemistry, vol. 282, no. 33, pp. 24131–24145, 2007.

[59] Y. A. Lee, L. A. Noon, K. M. Akat et al., “Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap,” Nature Communications, vol. 9, no. 1, p. 4962, 2018.

[60] Y. Wei, J. Zhou, J. Wu, and J. Huang, “ERβ promotes Aβ degradation via the modulation of autophagy,” Cell Death & Disease, vol. 10, no. 5, p. 565, 2019.